EGF and central nervous system cancer: Considering that different IDH-dependent glioma subtypes have different EGF activation status (Roth and Weller, 2014; Thorne et al., 2016), it is reasonable to identify such gene and its targeted probe as one of the potential markers for such IDH-dependent subtyping.